These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 29559478)

  • 21. Current studies of immunotherapy in head and neck cancer.
    Dogan V; Rieckmann T; Münscher A; Busch CJ
    Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
    Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
    Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
    Srinivasan P; Wu X; Basu M; Rossi C; Sandler AD
    PLoS Med; 2018 Jan; 15(1):e1002497. PubMed ID: 29377881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
    Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
    Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint.
    Xu S; Tao Z; Hai B; Liang H; Shi Y; Wang T; Song W; Chen Y; OuYang J; Chen J; Kong F; Dong Y; Jiang SW; Li W; Wang P; Yuan Z; Wan X; Wang C; Li W; Zhang X; Chen K
    Nat Commun; 2016 May; 7():11406. PubMed ID: 27147225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
    Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
    Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
    [No Abstract]   [Full Text] [Related]  

  • 27. Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis.
    Zhao T; Li C; Wu Y; Li B; Zhang B
    PLoS One; 2017; 12(4):e0176822. PubMed ID: 28453554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Abdel-Rahman O; Helbling D; Schmidt J; Petrausch U; Giryes A; Mehrabi A; Schöb O; Mannhart M; Oweira H
    Clin Oncol (R Coll Radiol); 2017 Apr; 29(4):218-230. PubMed ID: 27894673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
    Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
    Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
    Tan PS; Aguiar P; Haaland B; Lopes G
    Lung Cancer; 2018 Jan; 115():84-88. PubMed ID: 29290267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lower expression of PD-1 and PD-L1 in peripheral blood from patients with chronic ITP.
    Zhong J; Chen S; Xu L; Lai J; Liao Z; Zhang T; Yu Z; Lu Y; Yang L; Wu X; Li B; Li Y
    Hematology; 2016 Oct; 21(9):552-7. PubMed ID: 27077771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Managing immune checkpoint-blocking antibody side effects.
    Postow MA
    Am Soc Clin Oncol Educ Book; 2015; ():76-83. PubMed ID: 25993145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis.
    Huang G; Sun X; Liu D; Zhang Y; Zhang B; Xiao G; Li X; Gao X; Hu C; Wang M; Ren H; Qin S
    Oncotarget; 2018 Jan; 9(3):4239-4248. PubMed ID: 29423118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.
    Kumar R; Collins D; Dolly S; McDonald F; O'Brien MER; Yap TA
    Curr Probl Cancer; 2017; 41(2):111-124. PubMed ID: 28214087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
    Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
    Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulatory T cells: a potential target in cancer immunotherapy.
    Shitara K; Nishikawa H
    Ann N Y Acad Sci; 2018 Apr; 1417(1):104-115. PubMed ID: 29566262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation and Function of the PD-L1 Checkpoint.
    Sun C; Mezzadra R; Schumacher TN
    Immunity; 2018 Mar; 48(3):434-452. PubMed ID: 29562194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.
    Gettinger S; Horn L; Jackman D; Spigel D; Antonia S; Hellmann M; Powderly J; Heist R; Sequist LV; Smith DC; Leming P; Geese WJ; Yoon D; Li A; Brahmer J
    J Clin Oncol; 2018 Jun; 36(17):1675-1684. PubMed ID: 29570421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study.
    Kobayashi T; Iwama S; Yasuda Y; Okada N; Tsunekawa T; Onoue T; Takagi H; Hagiwara D; Ito Y; Morishita Y; Goto M; Suga H; Banno R; Yokota K; Hase T; Morise M; Hashimoto N; Ando M; Kiyoi H; Gotoh M; Ando Y; Akiyama M; Hasegawa Y; Arima H
    J Endocr Soc; 2018 Mar; 2(3):241-251. PubMed ID: 29600292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.